Condition (MeSH)
Mastocytosis
ClinicalTrials.gov lists 136 trials for Mastocytosis or a narrower condition beneath it. Blueprint Medicines Corporation has the most among industry and government lead sponsors, with 11.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
2 more sections with rows
49 of the 136 trials are tagged with Mastocytosis itself; the rest are tagged with a narrower condition beneath it.
When did Mastocytosis trials start? (33)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 8 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 6 |
| 2020 | 8 |
| 2019 | 4 |
| 2018 | 4 |
| 2017 | 1 |
Showing 10 of 33 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 37 months across 86 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mastocytosis trials in? (10)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 9 |
| Phase 1/2 | 6 |
| Phase 2 | 36 |
| Phase 2/3 | 5 |
| Phase 3 | 9 |
| Phase 4 | 2 |
| Not applicable | 16 |
| Observational | 49 |
| Expanded access | 2 |
| Unknown | 2 |
How many Mastocytosis trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 18 |
| Active, not recruiting | 7 |
| Available | 1 |
| Completed | 73 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mastocytosis trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Blueprint Medicines Corporation | 11 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 9 |
| Novartis Pharmaceuticals | 5 |
| AB Science | 4 |
| Cogent Biosciences, Inc. | 3 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Mastocytosis? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Avapritinib | 5 |
| Imatinib | 4 |
| Midostaurin | 4 |
| Bezuclastinib | 3 |
| Cytoxan | 3 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 8 |
| Total Body Irradiation | 7 |
| Mofetil Mycophenolate | 6 |
| Cyclosporine 0.05% | 5 |
| Peripheral blood stem cell transplantation | 5 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Mastocytosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 31 | 6 |
| Thrombocytopenia | 28 | 3 |
| Pyrexia | 26 | 3 |
| Anaemia | 21 | 3 |
| Febrile neutropenia | 21 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Mastocytosis? (43)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 43 publications.
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Mastocytosis | Point prevalence | 1-5 / 10 000 | Worldwide | Not stated | Exact |
| Mastocytosis | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Mastocytosis | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Mastocytosis | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Mastocytosis | Point prevalence | 1-9 / 100 000 | Denmark | Not stated | Exact |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Mastocytosis | 98292 | Exact | Orphadata Science knowledge files, Product 1 |
| Mastocytosis | 98292 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.